



The Bacterial Vaccines Network

Director:

Adam Cunningham

Co-Directors:

Ankur Mutreja, Constantino Lopez Macias & Francesca Micoli



Overview 26 November 2025

University of Birmingham, UK

BactiVac: mission to help reduce bacterial infections and AMR through vaccine development

Accelerating the development of vaccines against bacterial infections relevant to low- and middle-income countries (LMICs)


- >2350 members, 90+ countries
- 52% LMICs / Global South, 15% industry
- We provide **Catalyst grants** to **de-risk** projects
- Attract investment funding for LMICs / Global South
- Advocacy for developing and using bacterial vaccines
- Human and animal bacterial pathogens (**One Health**)
- Engagement & interaction with industry and others
- Bacterial pathogen agnostic, key is vaccine development / implementation down the pipeline



BactiVac: Where are we now

- Grown to over 2350 members since 2017
- Members from 92 different countries
- 52% based in LMICs, 15% industry

Distribution of BactiVac Members Globally



Number of projects funded	98
Total funding awarded	£4,963,975
Funding leveraged to support project delivery	£5,432,698 + 109%
Total follow-on funding leveraged by projects (49 awards from 28 projects)	£25,826,170 + 520%

BactiVac: What makes us different?

- Only bacterial vaccine focused network
- Major focus on LMICs / Global South
- Provide catalyst funding (approx. £70k) to derisk and grow projects
- Projects need to have at least two partners
- Provide catalyst training awards to address bottlenecks
- Provide training to upskill groups – enhance capacity, remove barriers
- Funding typically has ODA requirement – different sources, flexibility
- Support capacity building through travel bursaries for BactiVac events



UNIVERSITY OF
BIRMINGHAM



BactiVac: What mindset do we apply?

- **Bacterial vaccines** (not TB) and **people** (training) are our focus
- We are **region agnostic** – fund all global health areas
- Consider and fund One Health
- Pushing vaccines down pipeline key determinant
- Derisk and grow projects – uplift to LMIC / Global South projects



UNIVERSITY OF
BIRMINGHAM



BactiVac: funding criteria & other considerations

- ODA compliance, LMIC / Global South-led projects
- Clarity of concept
- IP considerations
- How project will catalyse vaccine development / implementation
- Deliverability / realistic – defined outcomes?
- How strong is the collaboration, new partnerships?
- Plan for follow-on funding – pathway to progress
- Career development
- Organisation contributions – financial (other) governance, applicant support



UNIVERSITY OF
BIRMINGHAM



BactiVac: For more information

 www.birmingham.ac.uk/bactivac

 bactivac@contacts.bham.ac.uk

 [@BactiVac](https://twitter.com/BactiVac)

 [Linkedin.com/company/bactivac](https://www.linkedin.com/company/bactivac)



UNIVERSITY OF
BIRMINGHAM

